Skip to main content
SpringerLink
Log in

Unerwünschte Wirkungen von Neuroleptika und ihr Einfluß auf die Lebensqualität schizophrener Patienten

  • Conference paper
Schizophrenie — Moderne Konzepte zu Diagnostik, Pathogenese und Therapie

Zusammenfassung

Seit der Entdeckung des ersten antipsychotisch wirksamen Medikamentes Chlorpromazin 1952 sind die Neuroleptika von primärer Bedeutung in der Behandlung schizophrener Patienten, ihr Nutzen ist sowohl bei akut psychotischen Patienten wie auch in der Langzeitbehandlung bzw. in der Rezidivprophylaxe in hunderten von doppelblind kontrollierten Studien gezeigt worden. Trotzdem nehmen nur 30–40% der chronisch schizophrenen Patienten regelmäßig ihre Neuroleptika ein. Neben der mangelnden Einsicht in die Krankheit und in die Notwendigkeit einer medikamentösen Therapie werden Nebenwirkungen als Grund für die niedrige Compliance vermutet (Hogan et al. 1983), aber nur die Untersuchung von Van Putten (1974) erbrachte eine signifikante Beziehung zu motorischen Nebenwirkungen, insbesondere der Akathisie.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Awad AG (1993) Subjective response to neuroleptics in schizophrenia. Schizophr Bull 19: 609–618

    Article  PubMed  CAS  Google Scholar 

  • Awad AG, Hogan TP (1994) Subjective respons to neuroleptics and the quality of life: implications for treatment outcome. Acta Psychiatr Scand [Suppl] 380: 27–32

    Article  CAS  Google Scholar 

  • Awad AG, Voruganti LNP, Heslegrave RJ (1995) The aims of antipsychotic medication. What are the and are they being achieved? CNS Drugs 4: 8–16

    Article  Google Scholar 

  • Bandelow B, Müller, P, Gaebel W, et al. (1990) Depressive syndroms in schizophrenic patients after discharge from hospital. Eur Arch Psychiatry Clin Neurosci 140: 113–120

    Article  Google Scholar 

  • Bandelow B, Müller P, Frick U, et al. (1992) Depressive syndroms in schizophrenic patients under neuroleptic therapy. Eur Arch Psychiatry Clin Neurosci 141: 291–295

    Article  Google Scholar 

  • Barnes TR, Curson DA, Liddle PF, Patel M (1989) The nature and prevalence of depression in chronic schizophrenic in-patients. Br J Psychiatry 154: 486–491

    Article  PubMed  CAS  Google Scholar 

  • Belmaker RH, Wald D (1977) Haloperidol in normals. Br J Psychiatry 131: 222–223

    Article  PubMed  CAS  Google Scholar 

  • Brown SL, Sweeney DR, Schwarz GE (1979) Differences in self-report and observed pleasure in drepression and schizophrenia. J Nerv Ment Dis 176: 410–415

    Article  Google Scholar 

  • Brown S, Roe M, Lane A, Gervin M, Morris M, Kinsella A, Larkin C, O’Callaghan E (1996) Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatr Scand 940: 118–124

    Article  Google Scholar 

  • Bullinger M, Kirchberger I, von Steinbüchel N (1993) Der Fragebogen Alltagsleben: ein Verfahren zur Erfassung der gesundheitsbezogenen Lebensqualität. Z Med Psychol 3: 121–132

    Google Scholar 

  • Craig TJ, van Natta PA (1976) Recognition of depressed affect in hospitalized psychiatric patients: staff and patient perceptions. Dis Nerv Sys 37: 561–566

    CAS  Google Scholar 

  • Craig TJ, Richardson MA, Pass R, Bregman Z (1985) Measurement of mood and effect in schizophrenic inpatients. Am J Psychiatry 142: 1272–1277

    PubMed  CAS  Google Scholar 

  • Diamond R (1985) Drugs and the quality of life: the patient’s point of view. J Clin Psychiatry 46: 29–35

    PubMed  CAS  Google Scholar 

  • Emerich DF, Sanberg PR (1991) Neuroleptic dysphoria. Biol Psychiatry 29: 201–203

    Article  PubMed  CAS  Google Scholar 

  • Franz M, Lis S, Plüddemann K, Gallhofer B (1997) Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. Br J Psychiatry 170: 422–425

    Article  PubMed  CAS  Google Scholar 

  • Gebhard R (1972) Veränderungen der subjektiven Befindlichkeit psychotischer Patienten unter neuroleptischer Therapie. Pharmacopsychiatry 5: 295–300

    Google Scholar 

  • Harrow M, Fichtner CG, Grossmann LS (1991) Neuroleptic depression in schizophrenia. Biol Psychiatry 30: 844–848

    Article  Google Scholar 

  • Heinrich K (1967) Zur Bedeutung des postremissiven Erschöpfungs-Syndroms für die Rehabilitation Schizophrener. Nervenarzt 38: 487–491

    PubMed  CAS  Google Scholar 

  • Helmchen H, Hippius H (1969) Pharmakogen Depressionen. In: Hippius H, Seibach H (Hrsg) Das Depressive Syndrom. Schattauer, Munich, S 443–448

    Google Scholar 

  • Hogan TP, Awad AG, Eastwood R (1983) A self report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 13: 177–183

    Article  PubMed  CAS  Google Scholar 

  • Jaeger J, Bitter I, Czobor P, Volavka J (1990) The measurement of subjective experience in schizophrenia: the subjective deficit syndrom scale. Comp Psychiatry 31: 216–226

    Article  CAS  Google Scholar 

  • Johnson DAW (1981) Studies of depressive symptoms in schizophrenia. The prevalence of depression and ist possible causes. Br J Psychiatry 139: 89–101

    Article  PubMed  CAS  Google Scholar 

  • Knights A, Hirsch SR (1981) Revealed depression and drug treatment for schizophrenia. Arch Gen Psychiatry 38: 806–811

    Article  PubMed  CAS  Google Scholar 

  • Lader M (1993) Neuroleptic induced deficit syndrome: old problem, new challenge. J Psychopharmacol 7: 392–393

    Article  PubMed  CAS  Google Scholar 

  • Larsen EB, Gerlach J (1996) Subjective experience of treatment, side-eefects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics. Acta Psychiatr Scand 93: 381–388

    Article  PubMed  CAS  Google Scholar 

  • Lewander T (1994) Neuroleptics and the neuroleptic-induced deficit syndrome. Acta Psychiatr Scand [Suppl 380]: 8–13

    Google Scholar 

  • Liddle PF and Barnes TRE (1988) The subjecitve experience of deficits in schizophrenia. Comp Psychiatry 29: 157–164

    Article  CAS  Google Scholar 

  • Lindström LH (1994) Long-term clinical and social outcome studies in schizophrenia in relation to the cognitive and emotional side effects of antipsychotic drugs. Acta Psychiatr Scand [Suppl 380]: 74–76

    Google Scholar 

  • Maurer Y, Dittrich A (1979) Vergleich von Selbst-und Fremdbeurteilung bei schizophrenen Patienten. Pharmacopsychiatry 12: 375–382

    Article  CAS  Google Scholar 

  • Meltzer HY, Burnett S, Bastani B, Ramirez LF (1990) Effects of six month of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Comm Psychiatry 4: 892–897

    Google Scholar 

  • Möller HJ, von Zerssen D (1981) Depressive Symptomatik im stationären Behandlungs-verlauf von 280 schizophrenen Patienten. Pharmacopsychiatry 14: 172–179

    Article  Google Scholar 

  • Naber D (1995) A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 10[Suppl 3]: 133–138

    PubMed  Google Scholar 

  • Naber D, Holzbach R, Perro C and Hippius H (1992a) Clinical management of clozapine patients in relation to efficacy and side-effects. Br J Psychiatry 160[Suppl 17]: 54–59

    Google Scholar 

  • Naber D, Gaussares C, Moeglen JM, Tremmel L, Bailey PE (1992b) Efficacy and tolera-bility of SDZ HDC 912, a partial dopamine D2 agonist, in the treatment of schizophrenia. In: Meltzer H (ed) Novel antipsychotic drugs. Raven Press, New York, pp 99–107

    Google Scholar 

  • Prosser ES, Csernansky JF, Kaplan J, Thiemann S, Becker TJ, Hollister LE (1987) Depression, Parkinsonian symptoms and negative symptoms in schizophrenic treated with neuroleptics. J Nerv Ment Dis 175: 100–105

    Article  PubMed  CAS  Google Scholar 

  • Rifkin A, Quitkin F, Klein DF (1975) Akinesia. A poorly recognized drug-induced extrapyramidal behavioral disorder. Arch Gen Psychiatry 32: 672–674

    Article  Google Scholar 

  • Selten JP, Sijben NES, van den Bosch RJ, Omloo-Vissen J, Warmerdam H (1993) The subjective experience of negative symptoms: a self-rating scale. Comp Psychiatry 34: 192–197

    Article  CAS  Google Scholar 

  • Van Putten T (1974) Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 31: 67–72

    Article  PubMed  Google Scholar 

  • Van Putten T (1978) Subjective response as a predictor of outcome in pharmacotherapy: the consumer has a point. Arch Gen Psychiatry 35: 477–480

    Article  PubMed  Google Scholar 

  • Van Putten T, May PR (1978) Akinetic depression: in schizophrenia. Arch Gen Psychiatry 35: 1101–1107

    Article  PubMed  Google Scholar 

  • Windgassen K (1992) Treatment with neuroleptics: the patient’s perspective. Acta Psychiatr Scand 86: 405–410

    Article  PubMed  CAS  Google Scholar 

  • Wise RA (1991) Neuroleptic-induced anhedonia. Recent studies. In: Tamminga CA, Schulz SC (eds) Advances in neuropsychiatry and psychopharmacology, vol 1. Schizophrenia research. Raven Press, New York, pp 323–331

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Psychiatrie und Psychotherapie, Universität Hamburg, Martinistraße 52, D-20246, Hamburg, Bundesrepublik Deutschland

    Prof. Dr. D. Naber

Authors
  1. Prof. Dr. D. Naber
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Psychiatrische Klinik und Poliklinik, Ludwig-Maximilians-Universität, Nußbaumstraße 7, D-80336, München, Bundesrepublik Deutschland

    Hans-Jürgen Möller  & Norbert Müller  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Wien

About this paper

Cite this paper

Naber, D. (1998). Unerwünschte Wirkungen von Neuroleptika und ihr Einfluß auf die Lebensqualität schizophrener Patienten. In: Möller, HJ., Müller, N. (eds) Schizophrenie — Moderne Konzepte zu Diagnostik, Pathogenese und Therapie. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6471-6_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-6471-6_18

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-83086-4

  • Online ISBN: 978-3-7091-6471-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation